OpenBind is partnering with the Alchemistry 2027 committee and OpenADMET on a new physics-based blind challenge designed to put free energy methods to the test in a real-world drug discovery setting.
The challenge particularly invites the free energy community to take part, but all methods are welcome.
Participants will receive 54 compounds from a real-world drug discovery programme run by the ASAP Discovery Consortium, together with a single X-ray structure, and will be challenged to predict their protein-ligand binding free energies.
Running from 1 November 2026 to 25 March 2027, the challenge will provide an open, prospective test of how well computational methods perform on previously unseen data..
